Showing 4991-5000 of 8223 results for "".
- Dermatologists, Skin Cancer Survivors Tell "Skin Cancers, Take a Hike!"https://practicaldermatology.com/news/dermatologists-skin-cancer-survivors-tell-skin-cancers-take-a-hike/2457695/To help raise awareness of skin cancer prevention and detection, 12 dermatologists, skin cancer survivors, and their family and friends will tell “Skin Cancer, Take a Hike!” during a four-day trek through remote Alaska. Starting Sunday, July 15, the hikers will trek more than 20 miles
- Dermtech's Noninvasive Melanoma Screen Improves Care, Lowers Costhttps://practicaldermatology.com/news/dermtechs-noninvasive-melanoma-screen-improves-care-lowers-cost/2457700/New research shows that DermTech’s Pigmented Lesion Assay (PLA) reduces cost while improving the care of patients with primary pigmented skin lesions suggestive of melanoma. The
- BrightGuard Installs Free Sunscreen Dispensers at New York City Public Pools and Beacheshttps://practicaldermatology.com/news/brightguard-installs-free-sunscreen-dispensers-at-new-york-city-public-pools-and-beaches/2457708/Through its ongoing partnership with non-profit sponsor and donor IMPACT Melanoma and sunscreen provider Coppertone, BrightGuard has installed 134 sunscreen dispensers throughout New York City (NYC) public pools and beaches. BrightGuard—the first aut
- FDA Approves Dermira's Qbrexza Cloth to Treat Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/fda-approves-delmiras-qbrexza-cloth-to-treat-primary-axillary-hyperhidrosis/2457709/The FDA has approved Qbrexza™ (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza is applied directly to the skin and is designed to block sweat production by inhib
- Dermatology Authority Adds Credentialing and Licensing Support Serviceshttps://practicaldermatology.com/news/dermatology-authority-adds-credentialing-and-licensing-support-services/2457711/Dermatology Authority has added credentialing and licensing to their list of support services. The requirements for licensing and credentialing differ from city to city, state to state, and procedure to procedure. Dermatology Authority keeps tab
- DermTech Initiating Study to Assess DNA Damage and Reversalhttps://practicaldermatology.com/news/dermtech-initiating-study-to-assess-dna-damage-and-reversal/2457712/DermTech, Inc. has initiated enrollment in a clinical study to assess DNA damage induced by an excimer laser and evaluate the potentia
- First EB Patient Enrolled in PK Study of Diacerein 1% Ointmenthttps://practicaldermatology.com/news/first-eb-patient-enrolled-in-pk-study-of-diacerein-1-ointment/2457716/The first patient has been enrolled in a new Phase 1 study evaluating the pharmacokinetics (PK) and safety of Castle Creek Pharmaceuticals’ diacerein 1% ointment (CCP-020) under maximum use conditions in patients with epidermolysis bullosa (EB)
- World Vitiligo Day: Ra Medical Highlights Potential of Technologyhttps://practicaldermatology.com/news/world-vitiligo-day-pharos-highlights-potential-of-technology/2457715/In light of World Vitiligo Day (June 25), it’s important to realize that hope is here for patients who suffer from this disease, says Ra Medical Systems. Painless treatment is a possibility with P
- FDA-Approved Label Update: Cosentyx Inhibits Progression of Joint Structural Damage in PsAhttps://practicaldermatology.com/news/fda-approved-label-update-cosentyx-inhibits-progression-of-joint-structural-damage-in-psa/2457718/The US FDA has approved a label update for Cosentyx® (secukinumab) from Novartis, including data that show the treatment significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA). The data will be a
- New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatologyhttps://practicaldermatology.com/news/new-patient-centered-panel-helps-biopharmx-define-its-role-in-the-future-of-dermatology/2457721/BioPharmX Corporation has formed a Special Advisory Council of thought leaders from various disciplines to help the company embrace patient centricity in its products, pricing, and market access considerations. The advisors, who bring decades of experience in fields beyond dermatology&mda